^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA E542

    i
    Entrez ID:
    5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations (NCI10217) (NCT03842228)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/21/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PIK3CA • BRCA1 • BRCA2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN
    |
    PIK3CA mutation • PTEN mutation • PALB2 mutation • CDK12 mutation • PIK3CA E545 • PIK3CA H1047 • BARD1 mutation • PIK3CA E542 • RAD51 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Aliqopa (copanlisib)
    Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world (SPEAR) (NCT05022342)
    Phase N/A
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    07/07/2023
    Initiation :
    10/27/2021
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    HER-2 • ER • PIK3CA • PGR
    |
    HR positive • HER-2 negative • PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA C420R • PIK3CA E545A • PIK3CA E545G • PIK3CA Q546 • PIK3CA Q546R
    |
    Piqray (alpelisib) • fulvestrant
    Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors (NCT02688881)
    Phase 4
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    02/05/2017
    Primary completion :
    12/30/2020
    Completion :
    02/24/2021
    PIK3CA • PTEN
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification
    |
    sirolimus
    Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer (NRG-GY008) (NCT02728258)
    Phase 2
    NRG Oncology
    Completed
    Last update posted :
    02/15/2022
    Initiation :
    09/16/2016
    Primary completion :
    08/18/2018
    Completion :
    02/14/2020
    PIK3CA
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L • PIK3CA M1043I • PIK3CA C420R • PIK3CA E545A • PIK3CA N345K • PIK3CA E545G • PIK3CA E545X • PIK3CA G1049R • PIK3CA H1047X • PIK3CA Q546 • PIK3CA Q546K • PIK3CA Q546R
    |
    Aliqopa (copanlisib)